文献速递肿瘤 PET/CT

[68Ga]Ga-DOTA-FAPI-04 PET/CT与[18F]FDG PET/CT在结直肠癌中的比较

Comparison of [68 Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-05-17

本研究纳入39例组织病理学确诊的原发或复发结直肠癌患者,同一周内分别行[18F]FDG与[68Ga]Ga-DOTA-FAPI-04 PET/CT显像,比较两者对原发灶、淋巴结及腹膜转移的诊断灵敏度。结果显示[68Ga]Ga-DOTA-FAPI-04 PET/CT在原发灶、淋巴结和腹膜转移检测中灵敏度和特异度更高,原发灶TBR及淋巴结SUVmax、TBR均显著高于[18F]FDG PET/CT。

要点

  • 39例结直肠癌患者同一周内行两种PET/CT,比较原发灶、淋巴结和腹膜转移检出。
  • [68Ga]Ga-DOTA-FAPI-04 PET/CT对原发灶灵敏度100%、特异度100%,[18F]FDG灵敏度100%、特异度85.3%。
  • 淋巴结检测[68Ga]Ga-DOTA-FAPI-04灵敏度90%、特异度100%,[18F]FDG灵敏度80%、特异度81.8%。

核心结论

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT在原发灶、尤其是淋巴结和腹膜转移检测中灵敏度和特异度更高,提示其可用于结直肠癌患者原发肿瘤和转移的常规临床评估。

研究设计与样本

  • 纳入39例组织病理学确诊的原发或复发结直肠癌患者,所有患者在同一周内均接受[18F]FDG和[68Ga]Ga-DOTA-FAPI-04 PET/CT显像。
  • 在两种显像上记录原发灶、淋巴结和转移灶,测量原发和转移灶的SUVmax及背景值并计算肿瘤/背景比值(TBR)进行比较。
  • 对未接受新辅助化疗而直接手术的患者,将手术结果与PET findings进行比较。

主要发现

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT评估原发肿瘤的灵敏度和特异度均为100%,[18F]FDG PET/CT灵敏度为100%、特异度为85.3%。
  • 以手术结果评估淋巴结检测,[68Ga]Ga-DOTA-FAPI-04 PET/CT灵敏度90%、特异度100%,[18F]FDG PET/CT灵敏度80%、特异度81.8%。
  • [68Ga]Ga-DOTA-FAPI PET/CT对腹膜植入灶的灵敏度和特异度均为100%,[18F]FDG PET/CT灵敏度为55%。
  • 原发灶SUVmax以[18F]FDG更高(p < 0.001),而TBR以[68Ga]Ga-DOTA-FAPI PET/CT更高(p=0.008)。
  • 淋巴结SUVmax和TBR在[68Ga]Ga-DOTA-FAPI PET/CT中均显著高于[18F]FDG PET/CT(两者p < 0.001)。

关键数值与推荐

  • 原发肿瘤:[68Ga]Ga-DOTA-FAPI-04 PET/CT灵敏度100%、特异度100%;[18F]FDG PET/CT灵敏度100%、特异度85.3%。
  • 淋巴结(以手术结果为参照):[68Ga]Ga-DOTA-FAPI-04 PET/CT灵敏度90%、特异度100%;[18F]FDG PET/CT灵敏度80%、特异度81.8%。
  • 腹膜植入灶:[68Ga]Ga-DOTA-FAPI PET/CT灵敏度100%、特异度100%;[18F]FDG PET/CT灵敏度55%。
  • 原发灶SUVmax:[18F]FDG高于[68Ga]Ga-DOTA-FAPI(p < 0.001);原发灶TBR:[68Ga]Ga-DOTA-FAPI高于[18F]FDG(p=0.008)。
  • 淋巴结SUVmax和TBR:[68Ga]Ga-DOTA-FAPI均显著高于[18F]FDG(两者p < 0.001)。

临床怎么用

  • 作者认为[68Ga]Ga-DOTA-FAPI-04 PET/CT在原发灶、尤其是淋巴结和腹膜转移检测中灵敏度和特异度更高,提示其可用于结直肠癌患者原发肿瘤和转移的常规临床评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: In this study, we aimed to evaluate the diagnostic sensitivity of [68 Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of primary or recurrent tumor, and nodal, peritoneal, and distant organ metastases in patients with newly diagnosed or relapsed colorectal cancer (CRC) in comparison with [18F]FDG PET/CT. MATERIALS AND METHOD: Thirty-nine patients with histopathologically confirmed primary or relapsed CRC were included in our study. All patients underwent both [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT imaging in the same week. Primary lesions, lymph nodes, and metastatic lesions were recorded on both scans. SUVmax and background values were measured from the primary and metastatic lesions; tumor-to-background ratio (TBR) was calculated and compared. The results of the operation were compared with PET findings in patients who underwent surgical treatment without neoadjuvant chemotherapy (NAC). RESULTS: The sensitivity and specificity of [68 Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of primary tumors were 100%, while the sensitivity of [18F]FDG PET/CT was 100% and its specificity was 85.3%. When evaluated with surgical results in the detection of lymph nodes, [68 Ga]Ga-DOTA-FAPI-04 PET/CT had a sensitivity of 90% and a specificity of 100%, whereas [18F]FDG PET/CT had a sensitivity of 80% and a specificity of 81.8%. The sensitivity and specificity of [68 Ga]Ga-DOTA-FAPI PET/CT for peritoneal implants were 100%, and the sensitivity of [18F]FDG PET/CT was 55%. The SUVmax of primary lesions was higher with [18F]FDG (p < 0.001), while TBR was higher in [68 Ga]Ga-DOTA-FAPI PET/CT than [18F]FDG PET/CT (p: 0.008). SUVmax and TBR of the lymph nodes were significantly higher in [68 Ga]Ga-DOTA-FAPI PET/CT than [18F]FDG PET/CT (p < 0.001 for both). CONCLUSION: [68 Ga]Ga-DOTA-FAPI-04 PET/CT achieved much higher sensitivity and specificity in the detection of primary lesions, and especially the lymph nodes and peritoneal metastases, suggesting that it can be employed in the assessment of primary tumor and metastases in patients with CRC in routine clinical practice.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kömek H, Can C, Kaplan İ, et al. Comparison of [68 Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer. Eur J Nucl Med Mol Imaging. 2022. PMID: 35578038. doi:10.1007/s00259-022-05839-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。